DNA Microarray Market Expected to Reach $3.6 Billion by 2006
FOSTER CITY, Calif., Nov. 13 The DNA microarray market is expected to reach $3.6 billion by 2006, driven largely by increasing adoption in the academic segment, greater throughput requirements in the pharmaceutical and biotechnology industries, and price reductions across all market segments. The scanner and arrayer markets will exhibit the largest growth, each increasing at a compound annual growth rate (CAGR) of 44% to reach $1.64 billion and $887 million respectively, according to a new Strategic Market Report(TM) from Front Line entitled DNA Microarrays: A Strategic Market Analysis, due out November 19, 2001. DNA microarrays are powerful new tools for investigating the mechanism of many diseases and accelerating the drug development process, which can last upwards of 15 years. The potential reduction in the pre-clinical drug development timeline can translate to substantial cost savings, while increasing a pharmaceutical manufacturer's potential market exclusivity.
While DNA microarrays will continue to be an essential tool for gene expression research, future applications will extend beyond the current pharmaceutical, biotechnology and academic user groups. By adopting microarrays in clinical diagnostics, physicians could detect genetic predispositions to specific diseases and customize treatment based on the patient's genetic make-up, substantially reducing treatment costs and improving quality of care.
Currently, costs are the largest barrier for widespread application of DNA microarray technology, however use should increase as prices decline over time. For example, growth in the integrated systems segment will occur at an average annual rate of 22%, driven by the price reduction of Affymetrix's GeneChip system, as well as by an increased use of pre-fabricated arrays in general as they become more affordable.
Affymetrix also dominates the arrayer market, and combined with Apogent and GeneMachines comprise 73% of that market. The 44% CAGR forecasted for this segment reflects the purchase of replacement and upgraded instruments, as well as additional arrayers to support greater throughput.
On the supply side of the market, trends include collaboration and globalization, as evidenced by the shift towards a universal microarray analysis platform. In fact, microarray technology companies have been actively consolidating as a strategy for building product portfolios and expanding market share. In addition, intellectual property disputes have resulted in mutual licensing agreements or joint ventures.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
